© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
January 23, 2021
Consistency of reporting quality attributes for biosimilars may differ, complicating the job of getting a full picture of biosimilarity.
January 14, 2021
A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.
January 12, 2021
Authors of a new study conclude that artificial intelligence could improve the selection of biosimilars for therapy.
January 02, 2021
Providers should feel confident using Mvasi, a bevacizumab biosimilar, for all indications of the reference product (Avastin), reviewers stated.